Osteopontin as novel biomarker for reversibility of pressure overload induced left ventricular hypertrophy

Biomark Med. 2020 May;14(7):513-523. doi: 10.2217/bmm-2019-0410. Epub 2020 May 28.

Abstract

Aim: The aim of this study was to evaluate the prognostic value of osteopontin (OPN) as a marker for left ventricular (LV) hypertrophy and its reversibility after surgical aortic valve replacement (SAVR). Patients & methods: Echocardiographic data and OPN plasma levels of 149 consecutive patients undergoing SAVR were obtained preoperatively and 3 months postoperatively. OPN was measured by Quantikine Human OPN immunoassay. Results: There was a significant correlation between higher OPN plasma levels and lower LV-mass regression. In patients receiving SAVR combined with coronary artery bypass grafting, high OPN plasma levels were also an indicator for eccentric hypertrophy phenotype. Conclusion: OPN may be a useful indicator for LV hypertrophy phenotype and could have a prognostic value to estimate LV-mass regression after SAVR.

Keywords: LVH; aortic stenosis; aortic valve replacement; cardiac remodeling; osteopontin; outcome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aortic Valve / surgery
  • Biomarkers / blood
  • Blood Pressure*
  • Electrocardiography
  • Female
  • Humans
  • Hypertrophy, Left Ventricular / blood*
  • Hypertrophy, Left Ventricular / physiopathology*
  • Hypertrophy, Left Ventricular / surgery
  • Male
  • Osteopontin / blood*
  • Phenotype
  • Preoperative Period
  • Risk

Substances

  • Biomarkers
  • Osteopontin